• 1
    Wilson P, Greenberg H. Interview of William Kannel, MD. Prog Cardiovasc Dis. 2010;53:49.
  • 2
    Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in framingham. J Chronic Dis. 1967;20:511524.
  • 3
    American Heart Association. Coronary Risk Handbook: Estimating Risk of Coronary Heart Disease in Daily Practice. New York, NY: American Heart Association; 1973.
  • 4
    Lemeshow S, Klar J, Teres D. Outcome prediction for individual intensive care patients: useful, misused, or abused? Intensive Care Med. 1995;21:770776.
  • 5
    Stern RH. The discordance of individual risk estimates and the reference class problem. arXiv:1001.2499v1[q-bio.QM]. Accessed January 30, 2012.
  • 6
    Gurm HS, Kaufman SR, Smith DE, et al. Different risk models predict markedly different probability of death for the same patient: implications of using risk models for individual patients. Eur Heart J. 2011;32(suppl 1):742.
  • 7
    Pepe M. Rejoinder to Nancy Cook’s comment on “measures to summarize and compare the predictive capacity of markers.” Int J Biostat. 2010; 6: Article 25. Accessed January 30, 2012.
  • 8
    Pepe MS. Problems with reclassification methods for evaluating prediction models. Am J Epidemiol. 2011;173:13271335.
  • 9
    Von Mises R. Probability, Statistics and Truth. New York, NY: Dover Publications, Inc; 1981: 17.
  • 10
    Mihaescu M, van Zitteren M, van Hoek M, et al. Improvement of risk prediction by genomic profiling: reclassicfication measures versus the area under the receiver operating characteristic curve. Am J Epidemiol. 2010;172:353361.
  • 11
    Kannel WB, D’Agostino RB, Sullivan L, Wilson PWF. Concept and usefulness of cardiovascular risk profiles. Am Heart J. 2004;148:1626.
  • 12
    Mihaescu R, van Hoek M, Sijbrands EJG, et al. Evaluation of risk prediction updates from commercial genome-wide scans. Genet Med. 2009;11:588594.
  • 13
    Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive services task force. Ann Intern Med. 2009;151:496507.
  • 14
    O’Malley PG, Redberg RF. Risk refinement, reclassification, and treatment thresholds in primary prevention of cardiovascular disease incremental progress but significant gaps remain. Arch Intern Med. 2010;170:16021603.
  • 15
    McTiernan A, Kuniyuki A, Yasui Y, et al. Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemol Biomarkers Prev. 1997;50:547556.
  • 16
    Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J. 2002;8:2327.
  • 17
    Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease, application to clinical and public health practice, a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499511.
  • 18
    Kooter AJ, Kostense PJ, Groenewold J, et al. Integrating information from novel risk factors with calculated risks the critical impact of risk factor prevalence. Circulation. 2011;124:741745.
  • 19
    Feinstein AR. Multivariable Analysis an Introduction. New Haven, CT: Yale University Press; 1996:566.